Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
Authors
Keywords
-
Journal
Biomed Research International
Volume 2016, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2016-05-30
DOI
10.1155/2016/7196280
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
- (2015) Antonio Gnoni et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma
- (2015) Zhong-Xia Wang et al. Hepatobiliary & Pancreatic Diseases International
- Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.
- (2015) Michela Del Prete et al. Oncotarget
- The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
- (2015) Luca Faloppi et al. Oncotarget
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
- (2014) Luca Faloppi et al. BMC CANCER
- Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis
- (2014) Nicola Silvestris et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
- (2014) Marco D'Anzeo et al. MOLECULES
- Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
- (2014) Daniele Santini et al. PLoS One
- Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
- (2013) Jie Sheng Chu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
- (2012) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
- (2012) Mario Scartozzi et al. PLoS One
- Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis
- (2011) Osamu Matsui et al. ABDOMINAL IMAGING
- Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy
- (2011) M. I. Koukourakis et al. CLINICAL CANCER RESEARCH
- Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
- (2011) Mario Scartozzi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy
- (2011) Nikolaus Kohles et al. TUMOR BIOLOGY
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors
- (2010) Luigi Fiume et al. PHARMACOLOGICAL RESEARCH
- Serological diagnostic factors for liver metastasis in patients with colorectal cancer
- (2010) Xiong-Zhi Wu WORLD JOURNAL OF GASTROENTEROLOGY
- Angiogenesis: From Chronic Liver Inflammation to Hepatocellular Carcinoma
- (2010) Paloma Sanz-Cameno et al. Journal of Oncology
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Lactate Dehydrogenase-5 (LDH-5) Expression in Human Gastric Cancer: Association with Hypoxia-Inducible Factor (HIF-1α) Pathway, Angiogenic Factors Production and Poor Prognosis
- (2008) Yanislav Kolev et al. ANNALS OF SURGICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started